Hemispherx secures replacement for blood cell supplier BioLife

By Gareth Macdonald

- Last updated on GMT

Hemispherx secures replacement for blood cell supplier BioLife

Related tags U.s. securities and exchange commission

Hemispherx has signed supply deals with US blood centres to address supply issues that delayed relaunch of genital wart drug, Alferon.

The New Jersey drugmaker confirmed this week that BioLife – a subsidiary of Baxalta –will no longer be supplying it with the leukocyte blood cells needed to produce Alferon, explaining that the company “was departing that particular area of its business.”

The announcement follows just weeks after Hemispherx reported in an US Securities and Exchange Commission (SEC) filing​ that supply problems were likely to delay the relaunch of Alferon on the US market by six months.

We had anticipated that it would take approximately until at least the 2nd half of 2015 before we would have Alferon approved for commercial sales; however, during the final stage of the manufacturing process we encountered issues regarding a change in both the contract supplier of leukocytes and regarding a reagent used in the formulation of Alferon.

Hemispherx added that: “We are currently resolving these issues and hope consequent delays will only extend our estimated time line by at least six months​.”

Replacement suppliers include Gulf Coast Regional Blood Centre in Houston, which begin shipping blood cells to Hemispherx’ revamped facility last Friday.

Hemispherx CFO Thomas Equels said: “BioLife's decision to shut down its Penn Plasma business arm before meeting BioLife's contract obligations to Hemispherx put us at risk.

We had to move quickly to ameliorate long term damages and redirect resources, seeking to avoid a prolonged delay in the production of Alferon​.”

The news comes just months after Hemispherx completed upgrades at its manufacturing facility in New Brunswick​, New Jersey.

It spent $8m (€7.1m) to replace six 100 litre reactors with a single 600 litre unit, which it said had allowed to cut the manpower needed to make Alferon by 80%.

Related news

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us


View more